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While p14ARF suppression of tumorigenesis in a p53-dependent manner is well studied, the mechanism by which p14ARF inhibits
tumorigenesis independently of p53 remains elusive. A variety of factors have been reported to play a role in this latter process. We report here that
p14ARF displays different effects on the anchorage-dependent and -independent growth of p53-null/Mdm2 wild type cells. p14ARF blocks both the
anchorage-dependent and-independent (soft agar) proliferation of 293T and p53−/− HCT116, but not p53-null H1299 lung carcinoma cells. While
p14ARF had no effect on the anchorage-dependent proliferation of p53−/− MEFs and Ras12V-transformed p53−/− MEFs, it inhibited the growth of
Ras12V-transformed p53−/− MEFs in soft agar. Furthermore, ectopic expression of p14ARF did not lead to degradation of the E2F1 protein and did
not result in the reduction of E2F1 activity detected by two E2F1 responsible promoters, Apaf1 and p14ARF promoter, in 293T, p53−/− HCT116,
and H1299 cells. This is consistent with our observations that p14ARF did not result in G1 arrest, but induced apoptosis via Bax up-regulation.
Taken together, our data demonstrate that the response of p53-null cells to ARF is cell type dependent and involves factors other than Mdm2 and
E2F1.
© 2006 Elsevier B.V. All rights reserved.Keywords: p14ARF; p53; Cell cycle; Tumor suppression1. Introduction
The INK4A/ARF locus on human chromosome 9p21 encodes
two tumor suppressors, p16INK4A and p14ARF, by alternative
splicing and the use of different reading frames [1,2]. They
function in the retinoblastoma (Rb) and p53 pathways
respectively [2–5].
The p14ARF (p19ARF for murine, referred to as ARF herein
for generic statements) [1,6] protein stabilizes p53 in response
to oncogenic signals. In primary fibroblasts, expression of
oncogenic Ras activates p53 in a p19ARF-dependent manner
[7,8]. Expression of other oncogenes in normal cells, including
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doi:10.1016/j.bbamcr.2006.04.011activation through ARF [9–13]. Furthermore, transgenic mice
heterozygous for p19ARF engineered to express c-myc in B-cells
exhibit accelerated B-cell lymphoma with loss of either p53 or
ARF function or amplification of Mdm2 [14], lending in vivo
support to the notion that ARF plays an essential role in
hyperproliferation-mediated p53 activation. Mechanistically,
ARF stabilizes p53 by interaction with Mdm2, the major player
in p53 destabilization in vivo. Homozygous deletion of mdm2
results in embryonic lethality in mice [15,16], which is rescued
by simultaneous deletion of p53 [15,16]. Mdm2 interacts with
the N-terminal region of p53, which contains the acidic
transcriptional activation domain [17]. This interaction results
in Mdm2 directly inhibiting the transcriptional activity of p53
[17], suppressing the p300/CBP-mediated p53 acetylation that
stabilizes p53 [18], ligating ubiqitins on p53 [19], and mediating
export of p53 from the nucleus into cytoplasmic proteasomes
for degradation [20,21]. p14ARF interacts directly with Mdm2,
thereby inhibiting the ubiquitin ligase activity of Mdm2 [22],
abolishing the inhibitory activity of Mdm2 on p53 acetylation
[18], and preventing Mdm2-mediated p53 export [23,24].
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multi-faceted effects of Mdm2 on p53. While it is still unclear
how p14ARF might sense oncogenic signals, c-Myc and E2F1
have been shown to up-regulate the death-associated protein
(DAP) kinase that activates p53 via p19ARF [25,26].
While compelling evidence supports a p53-dependent role of
p14ARF in tumor suppression, it has become clear recently that
ARF also inhibits cell proliferation in the absence of p53 [27–
31]. Both p53 and p14ARF are targeted for mutation in oral
squamous cell carcinoma [32]. Mice deficient for p19ARF
develop more fibrosarcomas than lymphomas, the reverse of the
tumor spectrum displayed by p53-null mice [33]. Furthermore,
ectopic expression of ARF inhibits the proliferation of p53-nullFig. 1. Ectopic p14ARF inhibits 293T cell proliferation. (A) Tetracycline (Tet) induci
(Materials and methods). The p14ARF protein was induced by doxycyclin (Dox) at 2
antibody (M2). The expression of E2F1, p21CIP1 (p21), p53, Mdm2, and actin was al
cells were cultured in the presence of Dox for 2 days, followed by immunofluorescen
(blue). (C) 105 pTET-1 (vector control), ARF2, and ARF3 of single cell clones of 293
without Dox for a period of 8 days with cell number being counted every 2 days. E
shown. Similar growth curves were also obtained for several other Tet-inducible p1
seeded in a 6-well plate, cultured with or without Dox (2 μg/ml) for 2 weeks, and stain
cell clones (data not shown). Experiments were repeated at least three times. (For inte
the web version of this article.)cells [27,28]. Although ARF inhibits tumorigenesis by
stabilization of p53 via inactivation of Mdm2, the mechanisms
by which ARF suppresses tumorigenesis independently of p53
is less clear. While ectopic p19ARF reduces the colony-
formation of p53-null MEFs but not those of p53−/−/Mdm2−/−
[27], enforced expression of p19ARF has been shown to inhibit
the proliferation of p53−/− Mdm2−/− MEFs but not p53−/−
MEFs [28]. Thus, the role of Mdm2 in mediating p53-
independent function of ARF remains elusive. p14ARF interacts
with and inhibits hypoxia-inducible factor-1α (HIF-1α)-medi-
ated transcription, a process that is independent of both p53 and
Mdm2 [31]. Both human and murine ARFs bind E2F1,
resulting in the degradation of E2F1 and the inhibition ofble 293Teton p14ARF cells were constructed and single cell clones were selected
μg/ml for the indicated times and detected by western blot using an anti-FLAG
so examined using specific antibodies. (B) 293Teton pTET-1 and 293Teton p14ARF
t staining for p14ARF using M2 (green). Nuclei were counter-stained with DAPI
Teton p14ARF cells were seeded in duplicate in 6-well plates and cultured with or
xperiments were repeated three times and the summary of these experiments is
4ARF single cell cones (data not shown). (D) 100 pTET-1 and ARF2 cells were
ed with 0.1% crystal violet. Identical results were also obtained using other single
rpretation of the references to colour in this figure legend, the reader is referred to
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independent function of ARF [30,34,35].
We report here a heterogeneous response of p53-null cells to
p14ARF. p14ARF inhibits both anchorage-dependent and
-independent growth of 293Tand p53−/− HCT116 cells, reduces
the proliferation of RasV12-transformed p53−/− MEFs on soft
agar but not on monolayer, and has no effect on either the
anchorage-dependent or -independent growth of H1299 p53-
null cells. As all these cells contain Mdm2 and we detected no
p14ARF-mediated alterations in E2F1 protein levels and its
activity in these cells, our research reveals the existence of
additional factors besides Mdm2 and E2F1 in regulating p53-
independent function of p14ARF.
2. Materials and methods
2.1. Materials, cell culture, and plasmids
HCT116 and p53−/− HCT116 cells were kindly provided by Dr. Bert
Vogelstein, Johns Hopkins Medical Institute. The p53−/−MEFs were gifted from
Dr. Tak Mak, University of Toronto. H1299 and 293Teton cells were purchased
from ATCC and Clontech, respectively. MEFs were cultured in DMEM (Gibco
BRL) containing β-mercaptoethanol (55 μM) and 10% fetal calf serum (FCS).
NIH3T3, 293T, 293Teton cells were cultured in DMEM, 10% FCS. HCT116 and
p53−/− HCT116 cells were cultured in McCoy's 5A, 10% FCS. H1299 cellsFig. 2. Ectopic p14ARF does not affect the anchorage-independent proliferation of p5
constructed using a retroviral system (Materials and methods) and the pooled populati
the expression of ectopic p14ARF, Mdm2, endogenous p19ARF, and actin using M2
hundred cells were seeded in 6-well plates in triplicate and cultured in the presence or
and numbers of colonies were graphed (right panel). The experiment was repeated tw
control retrovirus (pBabe) or a Ras12V retrovirus and selected in puromycin. Erk acti
cells were determined by western blot using specific antibodies (left panel). The growere cultured in RPMI1640, 10% FCS. Human p14ARF was cloned from C33A
cervical carcinoma cells by PCR amplification and expressed as a C-terminal
FLAG tagged protein using pcDNA3, pBabe, pTET-1, and pRevTRE vectors.
pTET-1 and pRevTRE are tetracycline-responsive vectors. pBabe and pRevTRE
are retroviral vectors. A retroviral vector expressing Teton (pRevTeton) was
purchased from Clontech. Plasmids expressing retroviral gag-pol (GP) and
VSV-G proteins were purchased from Stratagene. Apaf1 promoter luciferase and
p14ARF promoter luciferase constructs were kindly provided by Drs. Kristian
Helin and Kiyoshi Ohtani, respectively.
2.2. Retroviral infection
Retroviral infection was performed as we have published with
modifications [36–39]. Retroviral plasmid was co-transfected into 293T
cells with GP and VSV-G plasmids using a calcium phosphate method for
48 h. Virus-containing medium was harvested and used to infect target cells
in the presence of 10 μg/ml of polybrene (Sigma). Infected cells were
cultured in medium containing appropriate antibiotics. To determine
retrovirus titer, a LacZ retrovirus without a mammalian selection marker
was co-packed with a designated retrovirus at a ratio of 1:5 (LacZ : cDNA
of interest). Virus was used to infect NIH3T3 cells for 36 h before staining
for LacZ. Comparable levels of staining among individually packed
retroviruses indicate comparable titers.
2.3. Generation of tetracycline (Tet) inducible p14ARF expressing cell lines
The p53−/− MEFs were infected with pRevTeton retrovirus and selected in
G418 to yield p53−/− MEFTeton cells, which were then infected with pRevTet/3−/− MEFs. (A) Tet-inducible p53−/− MEFTeton p14ARF cells (passage 16) were
on was used. p14ARF was induced by Dox (2 μg/ml) for 2 days and examined for
antibody (for ectopic p14ARF) (left panel) and other specific antibodies. Two
absence of Dox for 2 weeks. The colonies were stained with 0.1% crystal violet
ice. (B) Tet-inducible p53−/− MEFTeton p14ARF cells were infected with either a
vation and the expression of Erk, Mdm2, endogenous p19ARF, and actin in those
wth rate of those cells was examined (right panel).
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MEFTeton p14ARF cells. The 293Teton p14ARF cells were constructed by
transfection of 293Teton cells with pTET-1/p14ARF using a calcium phosphate
method. Single cell clones were selected in hygromycin-containing medium.
Induction of p14ARF was carried out by addition of doxycycline, a Tet analogue.
2.4. Cell cycle analysis
Cell cycle distribution was determined by staining 293Teton p14ARF cells with
propidium iodide (PI) solution in the presence of RNase A overnight at 4 °C,
followed by the analysis of DNA contents using a flow cytometer [38].
2.5. Growth curve, colony formation, and soft agar assays
For growth curves, 105 293Teton p14ARF or 293Teton pTET-1 (control) cells
in duplicate were seeded in 6-well plates for 24 h before addition of Dox
(2 μg/ml). Cell numbers were counted every other day. To assess colony
formation, 100 to 200 cells were seeded into 6-well plates and cultured for
about 2 weeks with or without Dox until colonies formed, which were stained
with 0.1% crystal violet. For soft agar assay, 2 ml of 0.5% agar in DMEM,
10% FCS was plated in 6-well plates, followed by seeding 104 cells, which
were resuspended in 0.3% agar dissolved in DMEM, 10% FCS, on the top of
solidified agar. Cells were then cultured in a tissue culture incubator for
3 weeks supplemented with 100 μl media every 2 or 3 days until colonies
formed.
2.6. Cell lysis and western blot
Cell lysate was prepared and western blot performed according to our
published procedure [38]. Primary antibodies and concentrations used were:
anti-FLAG (M2 at 3 μg/ml, Sigma); anti-p53 (FL-353 at 1 μg/ml, Santa Cruz);
anti-E2F1 (1 μg/ml, Santa Cruz); anti-Actin (0.5 μg/ml, Santa Cruz); anti-
p21CIP1 (1 μg/ml, Santa Cruz); anti-p19ARF (5-C3-1, Santa Cruz); anti-MDM2
(SMP14, Santa Cruz).Fig. 3. p14ARF inhibits the anchorate-independent growth of 293T and RasV12 transf
cell clones, data not shown) of Tet-inducible 293Teton p14ARF cells and Ras12V tran
containing Dox (2 μg/ml). The MEFs were cultured for 2 days as monolayer with or
were cultured on soft agar for 3 weeks before being photographed.2.7. Immunofluorescent detection of p14ARF
Cells were fixed with pre-chilled Acetone/Methanol (3:7) and incubated for
2 h with affinity-purified antibodies: a monoclonal anti-FLAG antibody (M2 at
1 μg/ml, Sigma), followed by incubation with FITC-conjugated anti-mouse IgG
(1:200, Jackson Immnuno Research). Immunofluorescence was detected using a
fluorescent microscope (Carl Zeiss, Axiovert 200).
2.8. Luciferase assays
293Teton p14ARF cells were seeded in 24-well plate in triplicate, transfected
with 0.5 μg β-Gal, 0.5 μg Apaf1 or p14ARF luciferase constructs using PEI
(Sigma), followed by induction of p14ARF expression with Dox for 48 h before
assay for luciferase activity using the Stop and Glo Luciferase Assay Kit
(Promega). β-gal assays were performed as usual, and Luciferase Values were
then divided by β-gal values to normalize luciferase activity. For p53−/−
HCT116 and H1299 cells, they were seeded in 24-well plate in triplicate,
infected with pBabe or pBabe-p14ARF for 24 h, and then transfected with 0.5 μg
β-Gal and 0.5 μg Apaf1-luciferase using LipofectAMINE2000 (Invitrogen) for
30 h, which was followed by assay for β-gal and luciferase activity as described
above.3. Results
3.1. Expression of p14ARF attenuates the proliferation
of 293Teton cells
Although much is known about the mechanism by which
p14ARF functions in a p53-dependent manner, less is known
about its p53-independent function. To investigate this process,
a tetracycline (Tet)-inducible p14ARF (FLAG tagged) cell line
was constructed using 293Teton cells (derivatives of 293T cells).ormed p53−/− MEFs. The ARF2 (similar results were obtained from other single
sformed Tet-inducible p53−/− MEFTeton p14ARF cells were cultured in soft agar
without Dox before being seeded into a 6-well agar plate at 104 cells/well. Cells
Fig. 4. Ectopic p14ARF suppresses the anchorage-dependent and -independent
proliferation of p53−/− HCT116 colon cancer cells but not p53-null lung
carcinoma H1299 cells. HCT116, p53−/− HCT116, and H1299 cells were
infected with either a vector retrovirus (pBabe) or an ARF retrovirus (pBabe/
p14ARF) and selected in puromycin. (A) Expression of p14ARF, E2F1, Mdm2,
and actin in these cells after infection for 2 days was determined with western
blot using specific antibodies. (B) Colonies formed on monolayer for individual
cell population as indicated was determined. (C) The individual cell populations
after selection in puromycin for 2 days were seeded into puromycin-containing
soft agar and cultured for 3 weeks. Colonies numbers are graphed. Experiments
were repeated twice.
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12 h, which peaked at 2 days of Dox exposure (Fig. 1A). The
absence of p53 function, which is due to the expression of
adenovirus transforming proteins [40], in 293Teton cells was
confirmed. Etoposide (a DNA damage reagent) is unable to
further stabilize p53 and up-regulate p21CIP1 in 293Teton cells
(data not shown) and ectopic p14ARF was unable to up-regulate
either p53 or its transcriptional targets p21CIP1 and Mdm2 (Fig.
1A). Consistent with reports [23,24], ectopic p14ARF was
expressed largely in the nucleoli (Fig. 1B). To examine the
effects of ectopic p14ARF on 293Teton cell proliferation, we
examined the growth rate of 293Teton pTET-1 (control cells) and
293Teton p14ARF cells. Both cells were seeded at 105/well in 6-
well plates and cultured with or without Dox (2 μg/ml) for a
period of 8 days with cell numbers recorded every 2 days. While
Dox had no effect on the proliferation of 293Teton pTET-1 cells
(comparing the proliferation of these cells with and without Dox
addition), induction of p14ARF substantially inhibited 293Teton
p14ARF cells proliferation (Fig. 1C). The same results were also
obtained in at least 6 additional single cell clones (data not
shown), which validates the observed inhibition of p14ARF on
293T cell proliferation being not resulted from possible artifacts
of single cell cloning.
To consolidate this observation, a colony formation assay
was also performed. The plating efficiency of these cells was
first determined to permit the generation of 30 colonies in a 6-
well tissue culture plate. One hundred cells/well were
subsequently seeded in a 6-well plate and cultured with or
without Dox (2 μg/ml) for 2 weeks. The cell colonies were then
stained with 0.1% crystal violet. In comparison with the pTET-1
cells, Dox-induced ARF profoundly inhibited colony formation
in the ARF cells (Fig. 1D). Taken together, the above results
reveal that p14ARF inhibits 293Teton cell proliferation.
3.2. p14ARF inhibits the anchorage-independent but not
-dependent proliferation of p53−/− MEFs
Despite lack of any detectable function, the p53 protein is
highly expressed in 293Teton cells (Fig. 1A). To rule out any
contributions of the p53 protein toward ARF function in these
cells, we examined ARF function in p53−/− MEF cells. We
constructed Tet-inducible p14ARF expressing p53−/− MEFs
using late passage (p16) cells (for methodology, see Materials
and methods). While Dox induced the expression of p14ARF
protein in these cells (Fig. 2A, left penal), ARF did not reduce
either the growth rate (data not shown) or the efficiency of
colony formation (Fig. 2A, right panel). Consistent with a report
[10], p53−/− MEFs express high levels of endogenous p19ARF,
which was not affected by p14ARF induction (Fig. 2A, left
panel). In keeping with the observation that p14ARF did not
result in changes in Mdm2 expression in 293T cells (Fig. 1A),
induction of p14ARF did not affect Mdm2 expression in p53−/−
MEFs (Fig. 2A, left panel). However, as p14ARF inhibits the
proliferation of 293T (Fig. 1C, D) but not p53−/− MEF cells
(Fig. 2A, right panel), this implies that Mdm2 may not be the
major factor in modulating p53-independent function of
p14ARF. As the expression level of p14ARF induced by Dox inthese cells was substantially lower than that in 293Teton p14ARF
cells (data not shown), lack of inhibition on the proliferation of
p53−/− MEFs by p14ARF might be attributable in part to a low
level of the ARF protein.
293Teton cells are cancerous, while the late passage
(immortal) p53−/− MEFs are not. To investigate whether
transformation status of p53 non-functional cells is associated
with p14ARF-mediated growth inhibition, we infected Tet-
inducible p53−/− MEF p14ARF cells with either pBabe (an
empty vector control) or pBabe/Ras12V retrovirus. Compared
to pBabe infection, ectopic Ras12V induced typical spindle like
morphology (data not shown), indicative of cell transformation,
and Erk activation (Fig. 2B, left panel), as well as promoted
MEF proliferation (Fig. 2B, right panel). Consistent with Mdm2
up-regulation by the Ras/MEK/Erk pathway [41], RasV12
increased Mdm2 expression (Fig. 2B, left panel). Although
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[8], it did not increase p19ARF in p53−/− MEFs (Fig. 2B, left
panel), which may be attributable to the immortalization nature
of these cells (>passage 16). In comparison with parental cells,
induction of p14ARF by Dox was not altered by either pBabe or
Ras12V infection (data not shown). p14ARF induction had no
effect on the proliferation of RasV12 infected cells (Fig. 2B,
right panel) and on the colony formation of these cells (data not
shown). Thus, the transformation status of p53−/− MEFs does
not appear to dictate p14ARF function in these cells.
To further test this notion, the effect of ectopic p14ARF on the
anchorage-independent proliferation (in soft agar) of p53-null
cells was examined. Both Tet-inducible 293Teton p14ARF and
RasV12 transformed p53−/− MEFteton p14ARF cells were seeded
in soft agar with or without Dox (Fig. 3). Induction of p14ARF
clearly blocked the growth of both cells on soft agar (Fig. 3).
This is consistent with a recent report showing that p14ARF
prevented the tumor formation of H358 cells, p53-null
bronchioloalveolar lung adenocarcinoma, in nude mice [42].
Collectively, while the expression of p14ARF is not inhibitory to
the anchorage-dependent proliferation of Ras12V transformed
p53−/− MEFs, it prevents the growth of these cells in soft agar.
3.3. The p53-independent function of p14ARF is cell type
specific
The fact that ectopic p14ARF inhibits the anchorage-
dependent proliferation of 293T but not p53-null MEFs (Figs.
1, 2) reveals that p14ARF affects the proliferation of p53-null
cells in a cell-specific manner. To further address this issue, we
infected p53-null lung carcinoma H1299 [6,43] and colonFig. 5. The effects of p14ARF on E2F1 activity in p53-null function cells. 293Teton p1
p14ARF-luciferase (left two bars) and then induced for p14ARF expression by Dox (Ma
pBabe or p14ARF retrovirus and then transfected with β-Gal and Apaf1-luciferase (M
activity was normalized against β-Gal activity and the luciferase activity in p14ARF
Experiments were repeated at least twice and a representative of these is shown. The d
not statistically significant.cancer p53−/− HCT116 cells with pBabe and pBabe/p14ARF
retrovirus. The p53−/− HCT116 cells, kindly provided by Dr.
Vogelstein, were derived from HCT116 cells by homologous
recombination [44]. Expression of p14ARF in the infected cells
was confirmed (Fig. 4A). As expected, ectopic p14ARF up-
regulated Mdm2 (Fig. 4A), which was attributed through
p14ARF-mediated p53 stabilization. Compared to HCT116 cells,
p53−/− HCT116 was less sensitive to p14ARF-mediated
inhibition of anchorage-dependent and -independent growth
(Fig. 4B, C), an observation consistent with ARF's p53-
dependent function. Despite being expressed at a much higher
level in H1299 than in p53−/− HCT116 cells (Fig. 4A), p14ARF
reduces the anchorage-dependent and -independent growth of
p53−/− HCT116 but not H1299 cells (Fig. 4B, C). The reduction
in colony numbers of p14ARF-infected HCT116 and p53−/−
HCT116 cells on monolayer (Fig. 4B) and on soft agar (Fig. 4C)
was not due to lower titer of pBabe/p14ARF virus than that of
pBabe because compatible numbers of puromycin resistant
colonies were obtained from pBabe and p14ARF infected H1299
cells (Fig. 4B, C). This observation also reveals that p53 non-
functional H1299 cells are resistant to p14ARF-mediated
inhibition. The substantially lower level of p14ARF protein,
expressed in HCT116 cells than that expressed in p53−/−
HCT116 cells, was due to a p53-mediated negative-feedback
regulation on ARF [6,45]. Since Mdm2 levels in p53−/−
HCT116 and H1299 cells did not change with and without
ectopic p14ARF, Mdm2 does not play a major role in the
regulation of p53-independent function of ARF in thee two cell
lines. The fact that p14ARF was expressed at a much higher level
in the ARF non-functional H1299 cells than that in ARF
functional p53−/− HCT116 cells (Fig. 4A) may indicate a p53-4ARF cells were transfected with β-Gal and Apaf1-luciferase (right two bars) or
terials and methods) for 48 h. p53−/−HCT116 and H1299 cells were infected with
aterials and methods). After determining β-Gal and Apaf1-luciferase, luciferase
expressing cells was presented as % of the luciferase activity in control cells.
ifference in luciferase activity between cells with and without ARF expression is
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together, these observations demonstrate that the p53-indepen-
dent function of p14ARF is a rather complex issue.
3.4. p14ARF inhibits the proliferation of p53-null cells without
inducing E2F1 degradation
p19ARF has been reported to inhibit 293T cell proliferation
via the induction of E2F1 degradation [30]. To determine
whether this applies to p14ARF, we examined E2F1 protein in
multiple p53 non-functional cell lines with or without ectopic
p14ARF. It was found that p14ARF did not lead to down-
regulation of the E2F1 protein in 293Teton, p53−/− HCT116, and
H1299 cells (Figs. 1A and 4A), an observation consistent
with reports [34,35]. However, p14ARF has been reported to
inhibit the transcriptional activity of E2F1 in p53-null Saos2
cells without causing its down-regulation [34,35]. To examine
whether p14ARF inhibits E2F1 function in our system, weFig. 6. Ectopic p14ARF does not alter cell cycle distribution but induces apoptosis. (A)
cycle distribution was determined (38). (B) The ARF2 cells were induced for ARF ex
were counter-stained with DAPI (blue). The same results were also obtained using th
(For interpretation of the references to colour in this figure legend, the reader is refetransfected 293Teton p14ARF cells with a luciferase reporter
driven by either Apaf1 or p14ARF promoter, two E2F1
responsible promoters [46,47]. Induction of p14ARF by Dox
did not lead to inhibition of either promoter (Fig. 5). Similar
observation was also obtained in p53−/− HCT116, and H1299
cells (Fig. 5). Thus, our results are not consistent with
p14ARF-mediated inhibition of E2F1 activity observed in
Saos2 (p53-null ) cells [34,35]. This discrepancymight be caused
by the use of different p53 non-functional cell lines. Taken
together, the above data reveal the existence of factors besides
E2F1 in the regulation of p53-independent function of p14ARF.
3.5. p14ARF induces apoptosis in 293T cells via Bax
up-regulation
To characterize p14ARF-mediated inhibition of 293Teton cell
proliferation, we have examined whether p14ARF induces cell
cycle arrest. Upon induction of p14ARF from day 1 to day 4,The 293Teton p14ARF cells were treated with Dox (2 μg/ml) as indicated and cell
pression as indicated. Apoptotic cells were examined by TUNEL (green). Nuclei
ree other single cell clones (data not shown). Experiments were repeated twice.
rred to the web version of this article.)
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not observe any differences in cell cycle distribution among
mock and Dox-treated cells (Fig. 6A). This not only supports the
concept that p14ARF inhibits 293Tcell proliferation via an E2F1-
independent function but also suggests that p14ARF reduces
293T cell proliferation through the induction of apoptosis. This
is consistent with our observation that p14ARF-mediated
inhibition of 293T cell proliferation (Fig. 1C) was largely
compromised if initial cells were seeded at a higher density (106/
well) (data not shown). This also agrees with the fact that BrDU
labeling did not reveal significant differences with and without
p14ARF induction at this cell density (data not shown).
Collectively, the above observations suggest that p14ARF may
affect cell survival rather than cell proliferation.
To examine whether p14ARF induces 293T cell apoptosis, we
were able to show low levels of apoptosis following p14ARF-
induction (Fig. 6B). This agrees with the density-dependent
growth inhibition of 293T cells imposed by ectopic p14ARF. To
determine how p14ARF induces apoptosis in 293T cells, we
examined whether p14ARF facilitates the expression of Bcl-2
and two pro-apoptotic Bcl-2 family members (Bak and Bax)
with multiple BH (Bcl-2 homology) domains. While p14ARF
does not affect Bcl-2 and Bak expression, it increases Bax
expression between 1.5 to 2.5 fold (Fig. 7). Taken together, the
above data support the notion that p14ARF induces apoptosis in
293T cells via at least in part Bax up-regulation.
4. Discussion
Mounting evidence supports the concept of ARF possessing
functions that are independent of p53. Unlike the p53-
dependent functions, the mechanism by which ARF suppresses
tumorigenesis independently of p53 is poorly understood. A
variety of proteins have been reported to play a role in this
process, including Mdm2 [27,28], HIF-1α [31], E2F1
[30,34,35], Cdc25C [42], dihydrofolate reductase (DHFR)
[48], and nucleophosmin/B23 [49].Fig. 7. Ectopic expression of p14ARF up-regulates Bax in 293Teton p14ARF cells. ARF2
of ARF, Bax, Bak, Bcl-2, and actin by western blot using specific antibodies (left pan
p14ARF expression was confirmed (top, right panel). Bax expression was examinedWe have investigated ARF function in several p53-null
function cell lines, including 293Teton, p53−/− MEF, p53−/−
HCT116, and H1299. While ectopic p14ARF is functional in the
first three lines, it is not in H1299 cells. Although p19ARF
induces E2F1 protein degradation in 293T and MDA/MB231
p53 mutated cells [30], we did not observe a reduction in E2F1
protein by p14ARF in any of the p53-null cell lines used here.
Consistent with the observation of p19ARF inducing E2F1
degradation in U2OS (p53 wild type) cells [30], we found that
p14ARF induced approximately 90% and more than 50% E2F1
down-regulation in U2OS (data not shown) and HCT116 cells
(Fig. 4A), respectively. Knocking out p53 from HCT116 cells
abolished p14ARF-mediated down-regulation of E2F1 (Fig.
4A), demonstrating an important role of p53 in this process. The
difference between p19ARF and p14ARF in the induction of
E2F1 protein degradation in p53-null cells might be attributed
to the differences between these two ARFs [50,51]. While it was
reported that p14ARF did not induce E2F1 protein degradation,
its association with E2F1 inhibited the transcriptional activity of
E2F1 [34,35]. It is thus possible that murine and human ARF
inactivates E2F1 in the absence of p53 via different mechan-
isms. However, ectopic p14ARF does not arrest 293Teton cells in
G1 phase (Fig. 6A), consistent with the observation that p14ARF
did not reduce E2F1 activity in these cells (Fig. 5). Thus, E2F1
might not be a universal target of p14ARF in p53 deficient cells.
The fact that ectopic p14ARF was expressed to substantially
higher levels in H1299 than in p53−/− HCT116 cells (Fig. 4A)
suggests a negative-feedback regulation in p53−/− HCT116
cells, which is defective in H1299 cells. It will be of great
interests to determine the nature of this p53-independent ARF
feedback regulation.
While Mdm2 plays a major role in p14ARF-mediated p53
activation, it might not be involved in the p53-independent
function of ARF. Mdm2 has been reported to be required for
p19ARF function or to be inhibitory to p19ARF function in
p53−/− MEFs [27,28]. While we have found that p14ARF is not
inhibitory to the anchorage-dependent proliferation of p53−/−cells were induced for 2 days by Dox (2 μg/ml) and examined for the expression
el). The cells were also induced by Dox for a period of 8 days. The induction of
by western blot and plotted (right panel). Experiments were repeated twice.
795Y. Li et al. / Biochimica et Biophysica Acta 1763 (2006) 787–796MEFs, it blocks the anchorage-independent growth of RasV12
transformed p53−/− MEFs (Fig. 3). While the mechanism
underlying p14ARF-mediated inhibition of anchorage-indepen-
dent growth of RasV12 transformed p53−/− MEFs is unclear,
this observation may indicate a role of p14ARF in integrin
signaling. Furthermore, although p53-null MEF, p53−/−
HCT116 and H1299 cells are Mdm2 positive (Figs. 2, 4),
p14ARF inhibits the anchorage-independent proliferation of
p53−/− MEFs and p53−/− HCT116 but not H1299 cells (Figs.
3, 4). Thus, Mdm2 may not be a major factor in the regulation
of ARF function without p53. This is consistent with recent
developments showing that the interaction of ARF with Mdm2
in the nucleoplasm is required for ARF to activate p53.
Moreover, enforced localization of ARF to the nucleolus
abolishes the binding of ARF to Mdm2, and thereby leading to
the inability of ARF to activate p53 [49]. Furthermore, the
nucleolar location of ARF does not require p53 and inhibits
preribosomal RNA processing and nucleophosmin/B23 func-
tion [52–54]. Thus, our observation supports the existence of
additional factors besides Mdm2 in the regulation of ARF's
p53-independent function. Taken together, we provide evi-
dence here that ARF inhibits the proliferation of p53 deficient
cells in a cell-specific manner and this process involves
additional factors other than E2F1 and Mdm2.
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